Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Posts 5-Percent Organic Revenue Growth as Profits Rise 55.5 Percent

NEW YORK, April 28 (GenomeWeb News) - Molecular Devices today said that first-quarter revenue grew 5 percent organically as R&D spending declined 11.3 percent and profits rose 55.5 percent.

 

Total receipts for the three months ended March 31 rose around 2.5 percent to $40 million from $39 million year over year, hurt by foreign currency effects. Without these effects, revenue grew 5 percent, the company said.

 

The company said it "saw excellent growth" in its SpectraMax, FLIPR, and high- content imaging product lines during the quarter. But the firm said this growth was "somewhat offset" by a "weaker than expected" quarter in Europe.

 

"We remain confident, however, that our worldwide life sciences and drug discovery markets will remain stable in the near-term, and we do not expect this weakness to continue," President and CEO Joseph Keegan said in a statement.

 

R&D spending for the period declined to $5.5 million from $6.2 million year over year.

 

First-quarter profits more than doubled to $2.8 million, or $.17 per basic share, from $1.8 million, or $.11 per basic share, year over year.

 

Molecular Devices said it had around $33.2 million in cash and equivalents as of March 31.

 

Looking ahead, the company said it is poised to generate between $49 million and $51 million in second-quarter revenues, or growth of between 10.1 percent and 14.6 percent. Receipts for 2006, meantime, will likely be between $198 million and $206 million, or growth between 9.3 percent and 13.7 percent.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.